Video

Dr. Kim on the Multidisciplinary Management of HCC

Author(s):

Joseph Kim, MD, discusses the multidisciplinary management of hepatocellular carcinoma.

Joseph Kim, MD, professor of surgery and chief, Division of Surgical Oncology, University of Kentucky Markey Cancer Center, discusses the multidisciplinary management of hepatocellular carcinoma (HCC).

When patients with HCC present to Markey Cancer Center, their case is discussed at a multidisciplinary tumor board, Kim says. This is done in order for all health care professionals involved in the patient's treatment to present their expertise and formulate a treatment strategy.

It starts with the radiologist who interprets the imaging studies, followed by the pathologist who reviews the biopsy if one has been performed. Radiation oncologists, medical oncologists, and surgeons, which may include transplant surgeons and hepatobiliary surgeons, are involved in the optimal management of this disease, making treatment multidisciplinary in nature, Kim concludes.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.